Women's Cancer Study Group Gmbh

This Phase 3 trial tests whether the drug elacestrant can help prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The study compar…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study follows premenopausal women with a common type of early breast cancer to see how well different treatments work over time. Participants either receive hormone therapy (with or without ovarian suppression) or chemotherapy followed by hormone therapy. The goal is to unde…